Breaking News

Apceth bullish on manufacturing deal with bluebird bio

The German CDMO will operate as commercial manufacturer in Europe for Zynteglo, bluebird bio's first gene therapy to gain regulatory approval

Biocartis and BMS to collaborate on MSI testing with immuno-oncology therapies

Biocartis Group has signed a collaboration agreement with Bristol-Myers Squibb to register and use the Idylla MSI test in connection with immuno-on...

ASLAN and BioGenetics sign second commercialisation agreement

The partnership will see BioGenetics market ASLAN's DHODH in South Korea

Holding CAR-T cell therapies to a higher standard with ddPCR

Stringent quality control during manufacturing yields safer, more effective therapies, advise Mark White, Associate Director of Biopharma Product M...

Nestlé tackles phenylketonuria with Codexis enzyme

Codexis announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialisati...

Sanger Institute doubles known osteoarthritis genes

Scientists have doubled the number of known genetic links to osteoarthritis, opening up treatment potential

How to fuel the genetic medicine revolution

With multiple COVID-19 mRNA vaccination regimes now well-established and the first generation of DNA vaccines emerging, we can safely claim that a...

Opportunities to scale AAV viral vector production for gene therapies

Gene therapies hold tremendous potential as a treatment modality for inherited human diseases. This emerging therapeutic approach can correct or re...

Branched-chain amino acids found to regulate the development and progression of cancer

Researchers from A*STAR's SBIC have discovered how changes in BCAA metabolism influence the development and progression of tumours and pave the way...

Cytoreason and Pfizer to use machine learning model of the immune system for drug discovery

CytoReason, a leader in machine learning for drug discovery and development, has entered into a collaboration agreement with Pfizer that will lever...

Viral vector engineering to improve clinical performance and accelerate timelines for novel gene therapies

Viruses invade host cells and hijack their cellular machinery to direct the replication and transcription of their own genome. This makes them dang...

The increasing power of single-cell omics: changing the future of medicine

Advances in the single-cell genomic analysis of cells and tissues, including the required computational methods, have now put systematic, high-reso...

Surge in cell and gene therapy trials highlight the UK’s leading position as developmental hub in this innovative industry

Global industry shows confidence in cell and gene therapies and in UK’s ability to deliver these life-changing products

Multidimensional data analysis platforms: meeting new FDA calls for consistent evidence from CGT developers

Recent news that the US Food and Drug Administration (FDA) will ask cell and gene therapy (CGT) developers to provide more consistent evidence with...

Locate Bio is granted key US and EU patents for its IntraStem non-viral, next generation gene delivery technology

Locate Bio, a cell and gene therapy platform company developing a pipeline of regenerative medicine products, has received notification that it wil...

Towards the enzymatic synthesis of oligonucleotides: part II

By early 2020, ten oligonucleotide drugs had received US FDA regulatory approval; with many more in the pipeline, it’s only fair to say that this d...